GH Research (GHRS) Cash from Financing Activities (2021 - 2025)
GH Research (GHRS) posted quarterly Cash from Financing Activities of -$68000.0 for Q4 2025, down 15.25% year-over-year from -$80240.0 in Q4 2024, and down 3.03% quarter-over-quarter from -$66000.0 in Q3 2025.
GH Research (GHRS) Cash from Financing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$68000.0 for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 15.25% year-over-year to -$68000.0; the TTM figure through Dec 2025 stood at $139.7 million (up 46037.83% YoY), while the FY2025 annual figure was $139.7 million, up 46037.83% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$68000.0, down from -$66000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $286.6 million in Q4 2022, with the low at -$2.6 million in Q3 2021.
- The 5-year median for Cash from Financing Activities is -$68000.0 (2025), against an average of $32.7 million.
- Peak annual rise in Cash from Financing Activities reached 198491.55% in 2025, while the deepest fall reached 841.23% in 2025.
- GH Research's Cash from Financing Activities stood at -$171000.0 in 2021, then soared by 167712.87% to $286.6 million in 2022, then slumped by 100.02% to -$70000.0 in 2023, then advanced by 15.71% to -$59000.0 in 2024, then declined by 15.25% to -$68000.0 in 2025.
- Business Quant data shows GHRS's Cash from Financing Activities at -$68000.0 in Q4 2025, -$66000.0 in Q3 2025, and -$1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68,000.00 |
| Dec 31, 2025 | -68,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Dec 31, 2022 | 286.62 Mn |
| Dec 31, 2022 | 286.62 Mn |